Reading KALA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KALA free→Reading KALA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track KALA free→QuarterlyIQ Insights · KALA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Material Modification to Rights of Security Holders. To the extent required by
Unregistered Sales of Equity Securities. The matters described in
Entry into a Material Definitive Agreement. On March 3, 2026 (the “Effective Date”), KALA BIO, Inc. (the “Company”) and 2624465 Ontario Inc. o/a Younet AI, an Ontario corporation (“Younet”) entered into a Platform Development and Exclusive License Agreement (the “Agreement”) pursuant to which the Company obtained a worldwide exclusive license (the “Exclusive License”) of Younet’s proprietary, custom biomedical artificial intelligence research platform (the “Researgency Platform”), together wi…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On February 16, 2026, David Lazar notified KALA BIO, Inc. (the “ Company ”) of his decision to resign as a member of the Board of Directors of the Company, effective as of the same date. Mr. Lazar’s resignation from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices. 1 SIGNATURE Pursuant to the requirements of the S…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. On February 2, 2026, David Lazar tendered his resignation to the Board of the Directors (the “ Board ”) as the Chief Executive Officer and Chief Financial Officer of KALA BIO, Inc. (the “ Company ”), effective as of the same date. Mr. Lazar remains a director of the Board. On February 2, 2026, to fill the executive vacancy as a result of Mr. Lazar’s resignation as the Chief Executive Office…
of this Current Report on Form 8-K, pursuant to the terms of the Securities Purchase Agreement, upon the approval at the Annual Meeting of the Issuance Proposal and the Share Increase Proposal and the Second Closing, the five (5) nominees of AK Holdings were appointed as directors by the Board of Directors (the “ Board ”) upon the recommendation of the Nominating and Corporate Governance Committee: (A) Avi Minkowitz as a Class II director to serve until the 2028 annual meeting of stockholders…
The offering and sale of the Series AAA Preferred Stock was exempt from registration under Rule 506(b) of Regulation D and/or Rule 903 of Regulation S promulgated under the Securities Act. The sale of the Series AAA Preferred Stock by the Company in the Private Placement was not, nor will be registered under the Securities Act or any state securities laws and such shares may not be offered or sold in the United States absent registration with SEC or an applicable exemption from the registrati…
Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. As previously disclosed in the Company’s Current Report on Form 8-K filed on December 29, 2025, on December 19, 2025, each of (i) Marjan Farid, M.D. and Andrew I. Koven, who were Class I directors of the Company, (ii) Mark Iwicki and Todd Bazemore were Class II directors of the Company, and (iii) C. Daniel Meyers and Howard B. Rosen, who were Class III directors of the Company (collectively…
Entry into a Material Definitive Agreement. As previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (“ SEC ”) on November 25, 2025, KALA BIO, Inc. (the “ Company ”) previously entered into a Securities Purchase Agreement (the “ November 2025 Purchase Agreement ”), dated as of November 23, 2025, with the investor named therein (the “ Series AA Investor ”), pursuant to which the Company agreed to issue and sell, in a private placement, shares…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 20, 2026, KALA Bio, Inc. (the “ Company ”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business days between December 3, 2025, to January 16, 2026, the Company did not meet the minimum bid price of $1.00 per share required for continued l…
Entry into a Material Definitive Agreement. On January 8, 2026, KALA BIO, Inc. (the “ Company ”), entered into an At The Market Offering Agreement (the “ Sales Agreement ”) with H.C. Wainwright & Co., LLC (“ Wainwright ”) providing for the sale and issuance by the Company of shares of its common stock, par value $0.001 per share (the “ Common Stock ”) from time to time, through or to Wainwright as the Company’s sales agent or principal in an “at the market offering” program and as set forth i…
Unregistered Sales of Equity Securities On December 30, 2025, the Company issued an aggregate of 4,600,000 shares of Common Stock in private, unregistered transactions, including (i) 900,000 shares to Baker Bros. pursuant to the Baker Settlement, (ii) 2,200,000 shares to LifeSci pursuant to the LifeSci Settlement, and (iii) 1,100,000 shares to Delaware IR pursuant to the Delaware IR Settlement. The remaining 400,000 shares of Common Stock were issued to employees. The Company issued the share…
Entry into a Material Definitive Agreement On December 30, 2025, KALA BIO, Inc. (the “Company”) entered into a settlement agreement with Baker Bros. Advisors LP (“Baker Bros.”) under which the Company agreed to issue 900,000 shares of its common stock, par value $0.001 per share (“Common Stock”) to resolve certain claims relating to participation rights under prior financing arrangements (the “Baker Settlement”). In connection with the Baker Settlement, the Company and Baker Bros. also entere…
Changes in Registrant’s Certifying Accountant As previously disclosed in the Company’s Current Report on Form 8-K filed on December 16, 2025, the audit committee of the Company’s Board of Directors approved the dismissal of Deloitte & Touche LLP as the Company’s independent registered public accounting firm. On December 19, 2025, the Audit Committee approved the engagement of HTL International, LLC (“HTL”) as the Company’s independent registered public accounting firm for the fiscal year endi…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As disclosed in the Company’s Preliminary Proxy Statement for its 2025 annual meeting (the “2025 Annual Meeting”) as filed on December 19, 2025, each of Marjan Farid, M.D., Andrew I. Koven, C. Daniel Myers, Todd Bazmore, Mark Iwicki, and Howard B. Rosen tendered on December 19, 2025 a conditional resignation from their positions as director effecti…
Changes in Registrant’s Certifying Accountant On December 15, 2025, the Audit Committee of the Board of Directors of KALA BIO, Inc. (the “Company”) approved the dismissal of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm, effective as of December 15, 2025. The audit reports of Deloitte on the Company’s consolidated financial statements as of and for the fiscal years ended December 31, 2024 and 2023 did not contain an adverse opinion or a disc…
Other Events. Notice of Annual Meeting The Board of Directors of the Company has established January 30, 2026 as the date of the Company’s next annual meeting of stockholders (the “Annual Meeting”). The Company plans to publish additional details regarding the exact time, location and matters to be voted on at the Annual Meeting in the Company’s proxy statement for the Annual Meeting. Because the date of the Annual Meeting will change by more than 30 calendar days from the anniversary date of…
Entry into a Material Definitive Agreement. On December 4, 2025, KALA BIO, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Purchase Agreement ”) with a certain institutional investor (the “ Investor ”), pursuant to which the Company agreed to issue and sell in a registered direct offering (the “Offering”) (i) 900,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and (ii) pre-funded warrants (the “ Pre-Funded War…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Termination of Executive Officer On November 21, 2025, the Board terminated without cause the employment of Mary Reumuth, the Company’s Chief Financial Officer and Secretary, effective as of the business day following the First Closing. Appointment of Chief Executive Officer and Director In accordance with the Securities Purchase Agreement, on Nove…
Entry into a Material Definitive Agreement. Securities Purchase Agreement On November 23, 2025 (the “SPA Effective Date”), the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with the Investor, pursuant to which the Company agreed to issue and sell, in a private placement, shares (the “Series AA Preferred Shares”) of Series AA Convertible Non-Redeemable Preferred stock, par value $0.001 per share, of the Company (the “Series AA Preferred Stock”) and…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in
Based in part upon the representations of the Investor in the Securities Purchase Agreement, the offering and sale of the Placement Shares will be exempt from registration under Rule 903 of Regulation S promulgated under the Securities Act. In addition, it is expected that the offer and sale of the Settlement Stock will be exempt from registration under Section 4(a)(2) of the Securities Act, Rule 506 of Regulation D promulgated under the Securities Act, and corresponding provisions of state s…
Termination of a Material Definitive Agreement. The information contained in
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 10, 2025, KALA BIO, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(b)(2) (the “Minimum MVLS Requirement”) for continued listing on The Nasdaq Capital Market, as the market val…
Unregistered Sales of Equity Securities. The information set forth under
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.